Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730799 | 1.00 | SMYD3 (0.55) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL14730768 | 0.89 | RAB9A (0.50) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL14730766 | 0.89 | RAB9A (0.47) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL14730769 | 0.87 | RAB9A (0.46) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL14730798 | 0.87 | RAB9A (0.44) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL14730848 | 0.87 | RAB9A (0.45) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL14730796 | 0.86 | KDR (0.46) | SMYD3TLR7RAB9ANPC1TLR8 | |
| SCHEMBL14730722 | 0.86 | KDR (0.46) | SMYD3TLR7RAB9ANPC1TLR8 | |
| SCHEMBL14730764 | 0.85 | RAB9A (0.49) | SMYD3TLR9TLR7RAB9ANPC1 | |
| SCHEMBL16248395 | 0.84 | RAB9A (0.47) | TLR9TLR7RAB9ANPC1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | SMYD3 4127/4885TLR9 3787/4885TLR7 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.